Download PDF

Clinical Trial Results:
Phase II randomized, observer-blind, placebocontrolled, multi-country study in healthy non-pregnant women 18-45 years of age to evaluate the safety, reactogenicity and immunogenicity of a 1st intramuscular dose of GSK Biologicals’ investigational RSV maternal vaccine (GSK388550A) when given alone and given in co-administration with a single intramuscular dose of Boostrix (US formulation SB776423 or ex-US formulation SB263855) and to evaluate the safety, reactogenicity and immunogenicity of a 2nd dose of the RSV maternal vaccine.

Summary
EudraCT number	2019-002258-22
Trial protocol	BE
Global end of trial date	22 Nov 2021

Results information
Results version number	v1(current)
This version publication date	15 Dec 2022
First version publication date	15 Dec 2022
Other versions

Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information

Collapse all Expand all

Trial information

Top of page

Sponsor protocol code

209141

ISRCTN number

US NCT number

WHO universal trial number (UTN)

Sponsor organisation name

GlaxoSmithKline

Sponsor organisation address

Rue de l’Institut 89, Rixensart, Belgium, B-1330

Public contact

GSK Response Center, GlaxoSmithKline, 20 8664357343, GSKClinicalSupportHD@gsk.com

Scientific contact

GSK Response Center, GlaxoSmithKline, 20 8664357343, GSKClinicalSupportHD@gsk.com

Is trial part of an agreed paediatric investigation plan (PIP)

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?

Analysis stage

Final

Date of interim/final analysis

17 Feb 2022

Is this the analysis of the primary completion data?

Global end of trial reached?

Yes

Global end of trial date

22 Nov 2021

Was the trial ended prematurely?

Main objective of the trial

Safety: • To evaluate the safety and reactogenicity of 2 dose levels (60 and 120 μg) of RSVPreF3 when given alone or co-administered with dTpa from Vaccination up to Day 31. • To evaluate the safety of a 2nd dose of RSVPreF3 given from 12 up to 18 months post 1st dose up to Day 31 days post 2nd dose vaccination. Immunogenicity: • To evaluate the humoral immune response to 2 dose levels (60 and 120 μg) of RSVPreF3 when given alone and co-administered with dTpa, at Screening, Day 8 and Day 31 post 1st dose vaccination.

Protection of trial subjects

All subjects were supervised/observed for 60 minutes after vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that have no contraindications to any components of the vaccines. Subjects were followed-up for 181 days after each vaccination.

Background therapy

Evidence for comparator

Actual start date of recruitment

05 Nov 2019

Long term follow-up planned

Independent data monitoring committee (IDMC) involvement?

Number of subjects enrolled per country

Country: Number of subjects enrolled

United States: 257

Country: Number of subjects enrolled

Belgium: 146

Country: Number of subjects enrolled

Canada: 106

Worldwide total number of subjects

509

EEA total number of subjects

146

Number of subjects enrolled per age group

In utero

Preterm newborn - gestational age < 37 wk

Newborns (0-27 days)

Infants and toddlers (28 days-23 months)

Children (2-11 years)

Adolescents (12-17 years)

Adults (18-64 years)

509

From 65 to 84 years

85 years and over

Subject disposition

Top of page

Recruitment details

Screening details

Data reported in the participant flow, baseline characteristics and the immunogenicity outcome measures of the Extension Study were only analyzed for pooled groups, as the two formulations of dTpa vaccine (containing 300 micrograms(μg) or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.

Period 1 title

Primary Study

Is this the baseline period?

Yes

Allocation method

Randomised - controlled

Blinding used

Double blind

Roles blinded

Subject, Investigator, Monitor, Carer

Are arms mutually exclusive

Yes

RSV120_dTpa_RSV120(Pooled)

Arm description

Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and either one dose of 300 μg or 500 μg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Arm type

Experimental

Investigational medicinal product name

RSVPreF3 formulation 3 (120 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

dTpa - US formulation

Investigational medicinal product code

Other name

Boostrix - US formulation

Pharmaceutical forms

Suspension for injection in pre-filled syringe

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

dTpa - ex-US formulation

Investigational medicinal product code

Other name

Boostrix - ex-US formulation

Pharmaceutical forms

Suspension for injection in pre-filled syringe

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

RSV120_Placebo_RSV120(Pooled)

Arm description

Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Arm type

Placebo

Investigational medicinal product name

RSVPreF3 formulation 3 (120 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

NaCl

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

RSV60_dTpa_RSV120(Pooled)

Arm description

Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Arm type

Experimental

Investigational medicinal product name

RSVPreF3 formulation 2 (60 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

dTpa - US formulation

Investigational medicinal product code

Other name

Boostrix - US formulation

Pharmaceutical forms

Suspension for injection in pre-filled syringe

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

dTpa - ex-US formulation

Investigational medicinal product code

Other name

Boostrix - ex-US formulation

Pharmaceutical forms

Suspension for injection in pre-filled syringe

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

RSV60_Placebo_RSV120(Pooled)

Arm description

Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Arm type

Placebo

Investigational medicinal product name

RSVPreF3 formulation 2 (60 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

NaCl

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

dTpa_Placebo_RSV120(Pooled)

Arm description

Subjects received one dose of Placebo and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Arm type

Placebo

Investigational medicinal product name

dTpa - ex-US

Investigational medicinal product code

Other name

Boostrix - ex-US formulation

Pharmaceutical forms

Suspension for injection in pre-filled syringe

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

NaCl

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Investigational medicinal product name

dTpa - US

Investigational medicinal product code

Other name

Boostrix - US formulation

Pharmaceutical forms

Suspension for injection in pre-filled syringe

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Number of subjects in period 1	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Started	101	101	103	102	102
Completed	95	93	100	100	98
Not completed	6	8	3	2	4
ELIGIBILITY CRITERIA NOT FULFILLED	3	4	2	1	-
Lost to follow-up	3	4	1	1	4

Period 2 title

Extension Study

Is this the baseline period?

Allocation method

Randomised - controlled

Blinding used

Not blinded

Are arms mutually exclusive

Yes

RSV120_dTpa_RSV120(Pooled)

Arm description

Arm type

Experimental

Investigational medicinal product name

RSVPreF3 formulation 3 (120 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

RSV120_Placebo_RSV120(Pooled)

Arm description

Arm type

Placebo

Investigational medicinal product name

RSVPreF3 formulation 3 (120 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

RSV60_dTpa_RSV120(Pooled)

Arm description

Arm type

Experimental

Investigational medicinal product name

RSVPreF3 formulation 3 (120 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

RSV60_Placebo_RSV120(Pooled)

Arm description

Arm type

Placebo

Investigational medicinal product name

RSVPreF3 formulation 3 (120 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

dTpa_Placebo_RSV120(Pooled)

Arm description

Arm type

Placebo

Investigational medicinal product name

RSVPreF3 formulation 3 (120 μg)

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

One 0.5mL dose administered in the deltoid muscle.

Number of subjects in period 2 ^[1]	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Started	39	41	46	41	46
Completed	38	39	45	41	45
Not completed	1	2	1	0	1
Lost to follow-up	1	2	1	-	1

Notes
[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).

Baseline characteristics

Top of page

Reporting group title

RSV120_dTpa_RSV120(Pooled)

Reporting group description

Reporting group title

RSV120_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_dTpa_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

dTpa_Placebo_RSV120(Pooled)

Reporting group description

Reporting group values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)	Total
Number of subjects	101	101	103	102	102	509
Age categorical
Units: Subjects
In utero	0	0	0	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0	0	0	0
Newborns (0-27 days)	0	0	0	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0	0	0	0
Children (2-11 years)	0	0	0	0	0	0
Adolescents (12-17 years)	0	0	0	0	0	0
Adults (18-64 years)	101	101	103	102	102	509
From 65-84 years	0	0	0	0	0	0
85 years and over	0	0	0	0	0	0
Age Continuous
Age, Primary Study
Units: Years
arithmetic mean (standard deviation)	31.4 ± 7.6	31.0 ± 8.0	30.8 ± 8.4	30.5 ± 8.3	30.4 ± 7.9	-
Sex/Gender, Customized
Sex/Gender, Primary Study
Units: Participants
Female	101	101	103	102	102	509
Male	0	0	0	0	0	0
Race/Ethnicity, Customized
Race/Ethnicity, Primary Study
Units: Subjects
AMERICAN INDIAN OR ALASKA NATIVE	3	0	1	1	0	5
ASIAN	1	3	2	4	4	14
BLACK OR AFRICAN AMERICAN	4	6	8	3	4	25
OTHER Not specified	2	2	2	2	3	11
WHITE	91	90	90	92	91	454

Subject analysis set title

RSV120_dTpa_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of 500 μg dTpa vaccine (Ex-US formulation) on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) and were followed up until the study end.

Subject analysis set title

RSV120_Placebo_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of 500 μg dTpa vaccine (Ex-US formulation) on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Subject analysis set title

RSV60_Placebo_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects received one dose of Placebo and one dose of 500 μg dTpa vaccine (Ex-US formulation) on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Subject analysis set title

RSV120_dTpa_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of 300 μg dTpa vaccine (US formulation) on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Subject analysis set title

RSV120_Placebo_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of 300 μg dTpa vaccine (US formulation) on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Subject analysis set title

RSV60_Placebo_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subjects received one dose of Placebo and one dose of 300 μg dTpa vaccine (US formulation) on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.

Subject analysis set title

RSV120_dTpa_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis sets values	RSV120_dTpa_RSV120(EX-US)-SSS-Primary Study	RSV120_Placebo_RSV120(EX-US)-SSS-Primary Study	RSV60_dTpa_RSV120(EX-US)-SSS-Primary Study	RSV60_Placebo_RSV120(EX-US)-SSS-Primary Study	dTpa_Placebo_RSV120(EX-US)-SSS-Primary Study	RSV120_dTpa_RSV120(US)-SSS-Primary Study	RSV120_Placebo_RSV120(US)-SSS-Primary Study	RSV60_dTpa_RSV120(US)-SSS-Primary Study	RSV60_Placebo_RSV120(US)-SSS-Primary Study	dTpa_Placebo_RSV120(US)-SSS-Primary Study	RSV120_dTpa_RSV120(EX-US) - ES-Primary Study	RSV120_Placebo_RSV120(EX-US) - ES-Primary Study	RSV60_dTpa_RSV120(EX-US) - ES-Primary Study	RSV60_Placebo_RSV120(EX-US) - ES-Primary Study	dTpa_Placebo_RSV120(EX-US) - ES-Primary Study	RSV120_dTpa_RSV120(US) - ES-Primary Study	RSV120_Placebo_RSV120(US) - ES-Primary Study	RSV60_dTpa_RSV120(US) - ES-Primary Study	RSV60_Placebo_RSV120(US) - ES-Primary Study	dTpa_Placebo_RSV120(US) - ES-Primary Study	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects	50	49	51	51	49	51	52	52	51	50	50	49	51	51	51	51	52	52	51	51	49	51	51	51	51	51	51	52	51	51
Age categorical
Units: Subjects
In utero	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Newborns (0-27 days)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Children (2-11 years)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adolescents (12-17 years)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adults (18-64 years)	50	49	51	51	49	51	51	52	51	50	52	51	51	49	48	50	49	50	49	50	48	49	51	49	24	31	32	29	31	14
From 65-84 years	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
85 years and over	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Age Continuous
Age, Primary Study
Units: Years
arithmetic mean (standard deviation)	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±
Sex/Gender, Customized
Sex/Gender, Primary Study
Units: Participants
Female																			49
Male																			0
Race/Ethnicity, Customized
Race/Ethnicity, Primary Study
Units: Subjects
AMERICAN INDIAN OR ALASKA NATIVE
ASIAN
BLACK OR AFRICAN AMERICAN
OTHER Not specified
WHITE

End points

Top of page

Reporting group title

RSV120_dTpa_RSV120(Pooled)

Reporting group description

Reporting group title

RSV120_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_dTpa_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

dTpa_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

RSV120_dTpa_RSV120(Pooled)

Reporting group description

Reporting group title

RSV120_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_dTpa_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

dTpa_Placebo_RSV120(Pooled)

Reporting group description

Subject analysis set title

RSV120_dTpa_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(EX-US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(US)-SSS-Primary Study

Subject analysis set type

Safety analysis

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(EX-US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(US) - ES-Primary Study

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV120_dTpa_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV120_Placebo_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_dTpa_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

RSV60_Placebo_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Subject analysis set title

dTpa_Placebo_RSV120(US) - PPS-Primary Study

Subject analysis set type

Per protocol

Subject analysis set description

Primary: Percentage of subjects with any solicited local adverse event (AEs) [Primary Study]

Top of page

End point title

Percentage of subjects with any solicited local adverse event (AEs) [Primary Study] ^[1]

End point description

Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on the Solicited Safety Set (SSS) - Primary Study which consisted of all subjects from the Exposed set (ES) - Primary Study for whom solicited safety data were available.

End point type

Primary

End point timeframe

From Day 1 to Day 8

Notes
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	101	100	103	102	99
Units: Percentage of participants
number (confidence interval 95%)
RSVPreF3 (Left Arm), Erythema	5.9 (2.2 to 12.5)	5 (1.6 to 11.3)	5.8 (2.2 to 12.2)	5.9 (2.2 to 12.4)	0 (0 to 3.7)
RSVPreF3 (Left Arm), Pain	51.5 (41.3 to 61.6)	54 (43.7 to 64)	52.4 (42.4 to 62.4)	58.8 (48.6 to 68.5)	19.2 (12 to 28.3)
RSVPreF3 (Left Arm), Swelling	2 (0.2 to 7)	7 (2.9 to 13.9)	2.9 (0.6 to 8.3)	4.9 (1.6 to 11.1)	0 (0 to 3.7)
dTpa (Right Arm), Erythema	4 (1.1 to 9.8)	1 (0 to 5.4)	4.9 (1.6 to 11)	1 (0 to 5.3)	6.1 (2.3 to 12.7)
dTpa (Right Arm), Pain	81.2 (72.2 to 88.3)	25 (16.9 to 34.7)	76.7 (67.3 to 84.5)	18.6 (11.6 to 27.6)	78.8 (69.4 to 86.4)
dTpa (Right Arm), Swelling	5 (1.6 to 11.2)	0 (0 to 3.6)	1.9 (0.2 to 6.8)	1 (0 to 5.3)	4 (1.1 to 10)

No statistical analyses for this end point

Primary: Percentage of subjects with any solicited general AEs [Primary Study]

Top of page

End point title

Percentage of subjects with any solicited general AEs [Primary Study] ^[2]

End point description

Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever (body temperature ≥ 38 degree Celcius/100.4 degree Fahrenheit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on the SSS - Primary Study which consisted of all subjects from the ES - Primary Study for whom solicited safety data were available.

End point type

Primary

End point timeframe

From Day 1 to Day 8

Notes
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	101	101	103	102	99
Units: Percentage of participants
number (confidence interval 95%)
Fatigue	40.6 (30.9 to 50.8)	39.6 (30 to 49.8)	37.9 (28.5 to 48)	32.4 (23.4 to 42.3)	38.4 (28.8 to 48.7)
Gastrointestinal symptoms	23.8 (15.9 to 33.3)	28.7 (20.1 to 38.6)	27.2 (18.9 to 36.8)	28.4 (19.9 to 38.2)	28.3 (19.7 to 38.2)
Headache	44.6 (34.7 to 54.8)	45.5 (35.6 to 55.8)	35 (25.8 to 45)	39.2 (29.7 to 49.4)	37.4 (27.9 to 47.7)
Temperature	2 (0.2 to 7)	4 (1.1 to 9.8)	2.9 (0.6 to 8.3)	3.9 (1.1 to 9.7)	7.1 (2.9 to 14)

No statistical analyses for this end point

Primary: Percentage of subjects with any unsolicited AEs [Primary Study]

Top of page

End point title

Percentage of subjects with any unsolicited AEs [Primary Study] ^[3]

End point description

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on the ES - Primary Study which consisted of all subjects who received at least 1 dose of the study treatment.

End point type

Primary

End point timeframe

From Day 1 to Day 31

Notes
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	101	101	103	102	102
Units: Percentage of participants
number (confidence interval 95%)	38.6 (29.1 to 48.8)	34.7 (25.5 to 44.8)	33 (24.1 to 43)	37.3 (27.9 to 47.4)	32.4 (23.4 to 42.3)

No statistical analyses for this end point

Primary: Number of subjects with any SAEs [Primary Study]

Top of page

End point title

Number of subjects with any SAEs [Primary Study] ^[4]

End point description

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on the ES - Primary Study which consisted of all subjects who received at least 1 dose of the study treatment.

End point type

Primary

End point timeframe

From Day 1 to Day 31

Notes
[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	101	101	103	102	102
Units: Participants	0	0	0	0	0

No statistical analyses for this end point

Primary: Percentage of subjects with any solicited local AEs [Extension Study]

Top of page

End point title

Percentage of subjects with any solicited local AEs [Extension Study] ^[5]

End point description

Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies.The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on the SSS - Extension Study which consisted of all subjects from the ES - Extension Study for whom solicited safety data were available.

End point type

Primary

End point timeframe

From the Day of 2nd vaccination to Day 8 post 2nd vaccination

Notes
[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	39	39	46	41	44
Units: Percentage of participants
number (confidence interval 95%)
Erythema	17.9 (7.5 to 33.5)	10.3 (2.9 to 24.2)	8.7 (2.4 to 20.8)	14.6 (5.6 to 29.2)	2.3 (0.1 to 12)
Pain	87.2 (72.6 to 95.7)	87.2 (72.6 to 95.7)	80.4 (66.1 to 90.6)	85.4 (70.8 to 94.4)	38.6 (24.4 to 54.5)
Swelling	12.8 (4.3 to 27.4)	7.7 (1.6 to 20.9)	8.7 (2.4 to 20.8)	4.9 (0.6 to 16.5)	2.3 (0.1 to 12)

No statistical analyses for this end point

Primary: Percentage of subjects any solicited general AEs [Extension Period]

Top of page

End point title

Percentage of subjects any solicited general AEs [Extension Period] ^[6]

End point description

Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree Celcius/100.4 degree Fahrenheit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on the SSS - Extension Study which consisted of all subjects from the ES - Extension Study for whom solicited safety data were available.

End point type

Primary

End point timeframe

From the Day of 2nd vaccination to Day 8 post 2nd vaccination

Notes
[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	39	39	46	41	44
Units: Percentage of participants
number (confidence interval 95%)
Fatigue	25.6 (13 to 42.1)	33.3 (19.1 to 50.2)	37 (23.2 to 52.5)	46.3 (30.7 to 62.6)	34.1 (20.5 to 49.9)
Gastrointestinal symptoms	10.3 (2.9 to 24.2)	20.5 (9.3 to 36.5)	15.2 (6.3 to 28.9)	24.4 (12.4 to 40.3)	13.6 (5.2 to 27.4)
Headache	28.2 (15 to 44.9)	33.3 (19.1 to 50.2)	32.6 (19.5 to 48)	56.1 (39.7 to 71.5)	31.8 (18.6 to 47.6)
Temperature	0 (0 to 9)	0 (0 to 9)	2.2 (0.1 to 11.5)	9.8 (2.7 to 23.1)	2.3 (0.1 to 12)

No statistical analyses for this end point

Primary: Percentage of subjects with any unsolicited AEs [Extension Period]

Top of page

End point title

Percentage of subjects with any unsolicited AEs [Extension Period] ^[7]

End point description

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on ES - Extension Study which consisted of all subjects who received at least 2 doses of the study treatment.

End point type

Primary

End point timeframe

From the Day of 2nd vaccination to Day 31 post 2nd vaccination

Notes
[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	39	41	46	41	46
Units: Percentage of participants
number (confidence interval 95%)	18 (8 to 34)	20 (9 to 35)	20 (9 to 34)	29 (16 to 46)	20 (9 to 34)

No statistical analyses for this end point

Primary: Number of subjects with any SAEs [Extension Period]

Top of page

End point title

Number of subjects with any SAEs [Extension Period] ^[8]

End point description

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on ES - Extension Study which consisted of all subjects who received at least 2 doses of the study treatment.

End point type

Primary

End point timeframe

From the Day of 2nd vaccination to Day 31 post 2nd vaccination

Notes
[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	39	41	46	41	46
Units: Participants	0	0	0	1	0

No statistical analyses for this end point

Primary: RSV A neutralizing antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]

Top of page

End point title

RSV A neutralizing antibody Geometric Mean Titers (GMTs) at Screening [Primary Study] ^[9]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60 (Estimated Dilution 60). The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the Per Protocol Set (PPS) - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Primary

End point timeframe

At Screening (Day -7 to Day 1)

Notes
[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	100	100	103	102	102
Units: Titers (ED60)
geometric mean (confidence interval 95%)	875 (745 to 1027)	1022 (856 to 1222)	1135 (959 to 1342)	771 (673 to 883)	1050 (896 to 1231)

No statistical analyses for this end point

Primary: RSV A neutralizing antibody GMTs at Day 8 [Primary Study]

Top of page

End point title

RSV A neutralizing antibody GMTs at Day 8 [Primary Study] ^[10]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the Per Protocol Set (PPS) - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Primary

End point timeframe

At Day 8

Notes
[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	98	99	100	102	100
Units: Titers (ED 60)
geometric mean (confidence interval 95%)	14166 (12213 to 16431)	14285 (11999 to 17008)	10185 (8514 to 12183)	10590 (8994 to 12469)	783 (661 to 929)

No statistical analyses for this end point

Primary: RSV A neutralizing antibody GMTs at Day 31 [Primary Study]

Top of page

End point title

RSV A neutralizing antibody GMTs at Day 31 [Primary Study] ^[11]

End point description

End point type

Primary

End point timeframe

At Day 31

Notes
[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	98	97	102	99	97
Units: Titers (ED60)
geometric mean (confidence interval 95%)	9836 (8252 to 11725)	11038 (9160 to 13301)	9214 (7806 to 10876)	8739 (7561 to 10101)	845 (705 to 1013)

No statistical analyses for this end point

Primary: RSV PreF3 IgG antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]

Top of page

End point title

RSV PreF3 IgG antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study] ^[12]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA ). The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the Per Protocol Set (PPS) - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Primary

End point timeframe

At Screening (Day -7 to Day 1)

Notes
[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	100	100	103	102	102
Units: ELISA Units per milliliter (EU/mL)
geometric mean (confidence interval 95%)	6611 (5857 to 7461)	6751 (5982 to 7620)	7449 (6534 to 8492)	6172 (5570 to 6840)	6454 (5771 to 7217)

No statistical analyses for this end point

Primary: RSV PreF3 IgG GMCs at Day 8 [Primary Study]

Top of page

End point title

RSV PreF3 IgG GMCs at Day 8 [Primary Study] ^[13]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the Per Protocol Set (PPS) - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Primary

End point timeframe

At Day 8

Notes
[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	99	99	100	102	100
Units: EU/mL
geometric mean (confidence interval 95%)	156568 (137244 to 178613)	146708 (128639 to 167315)	101662 (89783 to 115113)	118670 (106004 to 132850)	5780 (5145 to 6494)

No statistical analyses for this end point

Primary: RSV PreF3 IgG GMCs at Day 31 [Primary Study]

Top of page

End point title

RSV PreF3 IgG GMCs at Day 31 [Primary Study] ^[14]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by Enzyme-linked immunosorbent assay (ELISA). Analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the Per Protocol Set (PPS) - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Primary

End point timeframe

At Day 31

Notes
[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	98	97	102	99	97
Units: EU/mL
geometric mean (confidence interval 95%)	101813 (89290 to 116092)	106082 (93597 to 120231)	86273 (77415 to 96145)	88938 (79738 to 99200)	6149 (5474 to 6908)

No statistical analyses for this end point

Secondary: Percentage of subjects with any solicited local adverse event (AEs) by each Boostrix formulation [Primary Study]

Top of page

End point title

Percentage of subjects with any solicited local adverse event (AEs) by each Boostrix formulation [Primary Study]

End point description

Assessed solicited local AEs are: erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3. The analysis was performed on the SSS - Primary Study which consisted of all subjects from the ES - Primary Study for whom solicited safety data were available.

End point type

Secondary

End point timeframe

From Day 1 to Day 8

End point values	RSV120_dTpa_RSV120(EX-US)-SSS-Primary Study	RSV120_Placebo_RSV120(EX-US)-SSS-Primary Study	RSV60_dTpa_RSV120(EX-US)-SSS-Primary Study	RSV60_Placebo_RSV120(EX-US)-SSS-Primary Study	dTpa_Placebo_RSV120(EX-US)-SSS-Primary Study	RSV120_dTpa_RSV120(US)-SSS-Primary Study	RSV120_Placebo_RSV120(US)-SSS-Primary Study	RSV60_dTpa_RSV120(US)-SSS-Primary Study	RSV60_Placebo_RSV120(US)-SSS-Primary Study	dTpa_Placebo_RSV120(US)-SSS-Primary Study
Number of subjects analysed	50	49	51	51	49	51	51	52	51	50
Units: Percentage of participants
number (confidence interval 95%)
Left Arm, Erythema	6 (1.3 to 16.5)	4.1 (0.5 to 14)	5.9 (1.2 to 16.2)	2 (0 to 10.4)	0 (0 to 7.3)	5.9 (1.2 to 16.2)	5.9 (1.2 to 16.2)	5.8 (1.2 to 15.9)	9.8 (3.3 to 21.4)	0 (0 to 7.1)
Left Arm, Pain	46 (31.8 to 60.7)	53.1 (38.3 to 67.5)	52.9 (38.5 to 67.1)	60.8 (46.1 to 74.2)	16.3 (7.3 to 29.7)	56.9 (42.2 to 70.7)	54.9 (40.3 to 68.9)	51.9 (37.6 to 66)	56.9 (42.2 to 70.7)	22 (11.5 to 36)
Left Arm, Swelling	2 (0.1 to 10.6)	6.1 (1.3 to 16.9)	3.9 (0.5 to 13.5)	2 (0 to 10.4)	0 (0 to 7.3)	2 (0 to 10.4)	7.8 (2.2 to 18.9)	1.9 (0 to 10.3)	7.8 (2.2 to 18.9)	0 (0 to 7.1)
Right Arm, Erythema	4 (0.5 to 13.7)	2 (0.1 to 10.9)	2 (0 to 10.4)	2 (0 to 10.4)	6.1 (1.3 to 16.9)	3.9 (0.5 to 13.5)	0 (0 to 7)	7.7 (2.1 to 18.5)	0 (0 to 7)	6 (1.3 to 16.5)
Right Arm, Pain	86 (73.3 to 94.2)	18.4 (8.8 to 32)	88.2 (76.1 to 95.6)	23.5 (12.8 to 37.5)	79.6 (65.7 to 89.8)	76.5 (62.5 to 87.2)	31.4 (19.1 to 45.9)	65.4 (50.9 to 78)	13.7 (5.7 to 26.3)	78 (64 to 88.5)
Right Arm, Swelling	6 (1.3 to 16.5)	0 (0 to 7.3)	3.9 (0.5 to 13.5)	2 (0 to 10.4)	6.1 (1.3 to 16.9)	3.9 (0.5 to 13.5)	0 (0 to 7)	0 (0 to 6.8)	0 (0 to 7)	2 (0.1 to 10.6)

No statistical analyses for this end point

Secondary: Percentage of subjects with any solicited general AEs by each Boostrix formulation [Primary Study]

Top of page

End point title

Percentage of subjects with any solicited general AEs by each Boostrix formulation [Primary Study]

End point description

Assessed solicited general AEs are: fatigue, gastrointestinal symptoms, headache and fever(body temperature ≥ 38 degree Celcius/100.4 degree Fahrenheit). Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3. The analysis was performed on the SSS - Primary Study which consisted of all subjects from the ES - Primary Study for whom solicited safety data were available.

End point type

Secondary

End point timeframe

From Day 1 to Day 8

End point values	RSV120_dTpa_RSV120(EX-US)-SSS-Primary Study	RSV120_Placebo_RSV120(EX-US)-SSS-Primary Study	RSV60_dTpa_RSV120(EX-US)-SSS-Primary Study	RSV60_Placebo_RSV120(EX-US)-SSS-Primary Study	dTpa_Placebo_RSV120(EX-US)-SSS-Primary Study	RSV120_dTpa_RSV120(US)-SSS-Primary Study	RSV120_Placebo_RSV120(US)-SSS-Primary Study	RSV60_dTpa_RSV120(US)-SSS-Primary Study	RSV60_Placebo_RSV120(US)-SSS-Primary Study	dTpa_Placebo_RSV120(US)-SSS-Primary Study
Number of subjects analysed	50	49	51	51	49	51	52	52	51	50
Units: Percentage of participants
number (confidence interval 95%)
Fatigue	36 (22.9 to 50.8)	36.7 (23.4 to 51.7)	39.2 (25.8 to 53.9)	29.4 (17.5 to 43.8)	34.7 (21.7 to 49.6)	45.1 (31.1 to 59.7)	42.3 (28.7 to 56.8)	36.5 (23.6 to 51)	35.3 (22.4 to 49.9)	42 (28.2 to 56.8)
Gastrointestinal symptoms	22 (11.5 to 36)	28.6 (16.6 to 43.3)	23.5 (12.8 to 37.5)	29.4 (17.5 to 43.8)	30.6 (18.3 to 45.4)	25.5 (14.3 to 39.6)	28.8 (17.1 to 43.1)	30.8 (18.7 to 45.1)	27.5 (15.9 to 41.7)	26 (14.6 to 40.3)
Headache	46 (31.8 to 60.7)	38.8 (25.2 to 53.8)	31.4 (19.1 to 45.9)	45.1 (31.1 to 59.7)	40.8 (27 to 55.8)	43.1 (29.3 to 57.8)	51.9 (37.6 to 66)	38.5 (25.3 to 53)	33.3 (20.8 to 47.9)	34 (21.2 to 48.8)
Temperature	4 (0.5 to 13.7)	6.1 (1.3 to 16.9)	3.9 (0.5 to 13.5)	5.9 (1.2 to 16.2)	12.2 (4.6 to 24.8)	0 (0 to 7)	1.9 (0 to 10.3)	1.9 (0 to 10.3)	2 (0 to 10.4)	2 (0.1 to 10.6)

No statistical analyses for this end point

Secondary: Percentage of subjects with any unsolicited AEs by each Boostrix formulation [Primary Study]

Top of page

End point title

Percentage of subjects with any unsolicited AEs by each Boostrix formulation [Primary Study]

End point description

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3. The analysis was performed on the ES - Primary Study which consisted of all subjects who received at least 1 dose of the study treatment.

End point type

Secondary

End point timeframe

From Day 1 to Day 31

End point values	RSV120_dTpa_RSV120(EX-US) - ES-Primary Study	RSV120_Placebo_RSV120(EX-US) - ES-Primary Study	RSV60_dTpa_RSV120(EX-US) - ES-Primary Study	RSV60_Placebo_RSV120(EX-US) - ES-Primary Study	dTpa_Placebo_RSV120(EX-US) - ES-Primary Study	RSV120_dTpa_RSV120(US) - ES-Primary Study	RSV120_Placebo_RSV120(US) - ES-Primary Study	RSV60_dTpa_RSV120(US) - ES-Primary Study	RSV60_Placebo_RSV120(US) - ES-Primary Study	dTpa_Placebo_RSV120(US) - ES-Primary Study
Number of subjects analysed	50	49	51	51	51	51	52	52	51	51
Units: Percentage of participants
number (confidence interval 95%)	38 (24.7 to 52.8)	36.7 (23.4 to 51.7)	39.2 (25.8 to 53.9)	43.1 (29.3 to 57.8)	33.3 (20.8 to 47.9)	39.2 (25.8 to 53.9)	32.7 (20.3 to 47.1)	26.9 (15.6 to 41)	31.4 (19.1 to 45.9)	31.4 (19.1 to 45.9)

No statistical analyses for this end point

Secondary: Number of subjects with any SAEs by each Boostrix formulation [Primary Study]

Top of page

End point title

Number of subjects with any SAEs by each Boostrix formulation [Primary Study]

End point description

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3. The analysis was performed on the ES - Primary Study which consisted of all subjects who received at least 1 dose of the study treatment.

End point type

Secondary

End point timeframe

From Day 1 to Day 31

End point values	RSV120_dTpa_RSV120(EX-US) - ES-Primary Study	RSV120_Placebo_RSV120(EX-US) - ES-Primary Study	RSV60_dTpa_RSV120(EX-US) - ES-Primary Study	RSV60_Placebo_RSV120(EX-US) - ES-Primary Study	dTpa_Placebo_RSV120(EX-US) - ES-Primary Study	RSV120_dTpa_RSV120(US) - ES-Primary Study	RSV120_Placebo_RSV120(US) - ES-Primary Study	RSV60_dTpa_RSV120(US) - ES-Primary Study	RSV60_Placebo_RSV120(US) - ES-Primary Study	dTpa_Placebo_RSV120(US) - ES-Primary Study
Number of subjects analysed	50	49	51	51	51	51	52	52	51	51
Units: Participants	0	0	0	0	0	0	0	0	0	0

No statistical analyses for this end point

Secondary: Number of subjects with any SAEs from 1st vaccination to Day 181 [Primary Study]

Top of page

End point title

Number of subjects with any SAEs from 1st vaccination to Day 181 [Primary Study]

End point description

End point type

Secondary

End point timeframe

From Day 1 to Day 181

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	101	101	103	102	102
Units: Participants	1	0	0	0	0

No statistical analyses for this end point

Secondary: Number of subjects with any SAEs from 1st vaccination to Day 181 by each Boostrix formulation [Primary Study]

Top of page

End point title

Number of subjects with any SAEs from 1st vaccination to Day 181 by each Boostrix formulation [Primary Study]

End point description

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the safety response to RSVPreF3. The analysis was performed on the ES - Primary Study which consisted of all subjects who received at least 1 dose of the study treatment.

End point type

Secondary

End point timeframe

From Day 1 to Day 181

End point values	RSV120_dTpa_RSV120(EX-US) - ES-Primary Study	RSV120_Placebo_RSV120(EX-US) - ES-Primary Study	RSV60_dTpa_RSV120(EX-US) - ES-Primary Study	RSV60_Placebo_RSV120(EX-US) - ES-Primary Study	dTpa_Placebo_RSV120(EX-US) - ES-Primary Study	RSV120_dTpa_RSV120(US) - ES-Primary Study	RSV120_Placebo_RSV120(US) - ES-Primary Study	RSV60_dTpa_RSV120(US) - ES-Primary Study	RSV60_Placebo_RSV120(US) - ES-Primary Study	dTpa_Placebo_RSV120(US) - ES-Primary Study
Number of subjects analysed	50	49	51	51	51	51	52	52	51	51
Units: Participants	1	0	0	0	0	0	0	0	0	0

No statistical analyses for this end point

Secondary: Number of subjects with any SAEs from 2nd vaccination to Day 181 post 2nd vaccination [Extension Period]

Top of page

End point title

Number of subjects with any SAEs from 2nd vaccination to Day 181 post 2nd vaccination [Extension Period]

End point description

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the safety response to RSVPreF3. The analysis was performed on ES - Extension Study which consisted of all subjects who received at least 2 doses of the study treatment.

End point type

Secondary

End point timeframe

From the Day of 2nd vaccination to Day 181 post 2nd vaccination

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	39	41	46	41	46
Units: Participants	0	0	0	1	0

No statistical analyses for this end point

Secondary: RSV A neutralizing GMTs at Screening by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV A neutralizing GMTs at Screening by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	49	51	51	51	51	51	52	51	51
Units: Titers (ED60)
geometric mean (confidence interval 95%)	777 (625 to 966)	1009 (798 to 1277)	989 (749 to 1307)	777 (631 to 956)	956 (740 to 1236)	981 (773 to 1245)	1035 (786 to 1362)	1298 (1070 to 1574)	765 (638 to 917)	1154 (952 to 1399)

No statistical analyses for this end point

Secondary: RSV A neutralizing GMTs at Day 8 by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV A neutralizing GMTs at Day 8 by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Day 8

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	48	50	51	51	49	51	50	51	49
Units: Titers (ED60)
geometric mean (confidence interval 95%)	14523 (11831 to 17827)	15458 (12424 to 19231)	10677 (8146 to 13993)	11128 (8885 to 13939)	698 (530 to 918)	13818 (11070 to 17248)	13264 (10075 to 17462)	9715 (7612 to 12400)	10077 (7897 to 12858)	884 (722 to 1082)

No statistical analyses for this end point

Secondary: RSV A neutralizing GMTs at Day 31 by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV A neutralizing GMTs at Day 31 by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Day 31

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	48	51	50	48	49	49	51	49	49
Units: Titers (ED60)
geometric mean (confidence interval 95%)	9838 (7987 to 12118)	10800 (8675 to 13446)	8754 (6821 to 11236)	8141 (6545 to 10125)	767 (575 to 1023)	9834 (7354 to 13152)	11276 (8283 to 15351)	9698 (7735 to 12159)	9395 (7726 to 11425)	930 (740 to 1168)

No statistical analyses for this end point

Secondary: RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At a single timepoint between 12 to 18 months post 1st vaccination

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	24	31	32	29	31	14	9	14	12	15
Units: Titers (ED60)
geometric mean (confidence interval 95%)	2034 (1458 to 2836)	2869 (1998 to 4119)	3086 (2143 to 4445)	2200 (1522 to 3180)	675 (495 to 920)	2014 (1190 to 3411)	2960 (1190 to 7362)	2474 (1741 to 3517)	2569 (1586 to 4160)	969 (602 to 1560)

No statistical analyses for this end point

Secondary: RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

Top of page

End point title

RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. Analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At a single timepoint between 12 to 18 months post 1st vaccination

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	38	40	46	41	46
Units: Titers (ED60)
geometric mean (confidence interval 95%)	2027 (1546 to 2656)	2889 (2086 to 4001)	2885 (2204 to 3778)	2302 (1730 to 3064)	759 (588 to 980)

No statistical analyses for this end point

Secondary: RSV A neutralizing GMTs at Day 31 post 2nd vaccination [Extension Study]

Top of page

End point title

RSV A neutralizing GMTs at Day 31 post 2nd vaccination [Extension Study]

End point description

Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay and titers are expressed in ED60. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Extension Study which consisted of all subjects from the ES - Extension Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Day 31 post 2nd vaccination

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	38	37	44	39	42
Units: Titers (ED60)
geometric mean (confidence interval 95%)	3892 (3016 to 5022)	5071 (3848 to 6683)	4779 (3747 to 6094)	4920 (3886 to 6231)	8200 (6380 to 10539)

No statistical analyses for this end point

Secondary: RSV PreF3 IgG GMCs at Screening by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV PreF3 IgG GMCs at Screening by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum), as the objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of dTpa (Boostrix) formulation on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	49	51	51	51	51	51	52	51	51
Units: EU/mL
geometric mean (confidence interval 95%)	6240 (5159 to 7548)	6524 (5597 to 7604)	7237 (5905 to 8869)	6106 (5275 to 7067)	5907 (5077 to 6873)	6987 (5975 to 8170)	6978 (5764 to 8447)	7662 (6447 to 9107)	6240 (5375 to 7245)	7051 (5973 to 8324)

No statistical analyses for this end point

Secondary: RSV PreF3 IgG GMCs at Day 8 by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV PreF3 IgG GMCs at Day 8 by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Day 8

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	48	50	51	51	50	51	50	51	49
Units: EU/mL
geometric mean (confidence interval 95%)	155721 (133435 to 181728)	143104 (126138 to 162352)	100064 (84699 to 118216)	123475 (107405 to 141950)	5523 (4700 to 6490)	157403 (126554 to 195772)	150184 (119250 to 189142)	103286 (85400 to 124919)	114053 (95089 to 136799)	6061 (5097 to 7207)

No statistical analyses for this end point

Secondary: RSV PreF3 IgG GMCs at Day 31 by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV PreF3 IgG GMCs at Day 31 by each Boostrix formulation [Primary Study]

End point description

End point type

Secondary

End point timeframe

At Day 31

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	48	51	49	48	49	49	51	49	49
Units: EU/mL
geometric mean (confidence interval 95%)	94254 (80742 to 110026)	95113 (83282 to 108624)	84509 (72281 to 98805)	81915 (70291 to 95460)	5600 (4777 to 6565)	109978 (88643 to 136446)	118052 (95525 to 145892)	88075 (75406 to 102872)	96727 (82608 to 113258)	6739 (5678 to 7999)

No statistical analyses for this end point

Secondary: RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

Top of page

End point title

RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. The analysis of this outcome measure was reported for each formulation of the Boostrix (300 μg or 500 μg of aluminum). The objective of this endpoint was to analyze the impact of co-administration of RSVPreF3 with either 300 μg or 500 μg of Boostrix formulation on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At a single timepoint between 12 to 18 months post 1st vaccination

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV120_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_Placebo_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV120_Placebo_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	RSV60_Placebo_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	24	31	32	29	31	14	9	14	12	15
Units: EU/mL
geometric mean (confidence interval 95%)	18832 (15141 to 23423)	20894 (16466 to 26512)	23189 (18629 to 28864)	20720 (16689 to 25726)	5014 (3932 to 6392)	18127 (10969 to 29958)	19641 (9143 to 42195)	22905 (17801 to 29471)	22233 (15931 to 31029)	6811 (5005 to 9269)

No statistical analyses for this end point

Secondary: RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

Top of page

End point title

RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody concentration is expressed in EU/mL. The cut-off value for the assay is 25 EU/mL. Analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At a single timepoint between 12 to 18 months post 1st vaccination

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	38	40	46	41	46
Units: EU/mL
geometric mean (confidence interval 95%)	18570 (14961 to 23049)	20605 (16333 to 25995)	23102 (19586 to 27249)	21152 (17777 to 25168)	5540 (4581 to 6700)

No statistical analyses for this end point

Secondary: RSV PreF3 IgG GMCs at Day 31 post 2nd vaccination [Extension Study]

Top of page

End point title

RSV PreF3 IgG GMCs at Day 31 post 2nd vaccination [Extension Study]

End point description

Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The analysis of this outcome measure was reported for the Pooled groups as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies, as the objective of this endpoint was to analyze the impact of the co-administration of RSVPreF3 with dTpa (Boostrix) (both formulations together) on the immunogenicity response to RSVPreF3. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Day 31 post 2nd vaccination

End point values	RSV120_dTpa_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	38	37	44	39	42
Units: (IU/mL)
geometric mean (confidence interval 95%)	41399 (34806 to 49241)	42943 (37226 to 49537)	43977 (38784 to 49865)	45680 (38574 to 54094)	86934 (75442 to 100177)

No statistical analyses for this end point

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Screening by each Boostrix formulation [Primary Study]

Top of page

End point title

Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Screening by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum). The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	51	51	51	52	51
Units: International Units Per mL (IU/mL)
geometric mean (confidence interval 95%)
anti-PT	7.39 (5.11 to 10.68)	7.64 (5.47 to 10.66)	6.65 (4.66 to 9.47)	7.55 (5.34 to 10.66)	5.66 (4.06 to 7.88)	7.17 (4.94 to 10.41)
anti-FHA	32.8 (23 to 46.7)	34.5 (24.3 to 49.1)	29.3 (22 to 38.9)	31 (22.7 to 42.4)	29.6 (22.5 to 38.9)	28 (21 to 37.4)
anti-PRN	43.2 (27.9 to 66.7)	39 (25.3 to 60.1)	28.1 (18.2 to 43.4)	42.1 (27.6 to 64.2)	40.1 (26.9 to 60)	28.7 (17.9 to 46.1)

No statistical analyses for this end point

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Day 31 by each Boostrix formulation [Primary Study]

Top of page

End point title

Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Day 31 by each Boostrix formulation [Primary Study]

End point description

End point type

Secondary

End point timeframe

At Day 31

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	51	48	49	51	49
Units: (IU/mL)
geometric mean (confidence interval 95%)
anti-PT	57.36 (41.82 to 78.69)	54.95 (44.78 to 67.44)	79.16 (62.67 to 99.98)	43.76 (34.1 to 56.17)	36.98 (28.25 to 48.42)	44.99 (34.81 to 58.15)
anti-FHA	237.1 (194.1 to 289.5)	210.6 (168.5 to 263.1)	303.6 (241.6 to 381.5)	186.5 (149.8 to 232.3)	176.7 (139.3 to 224.1)	232.9 (182.2 to 297.8)
anti-PRN	309.5 (226.7 to 422.6)	214.7 (166.8 to 276.4)	395.1 (290.3 to 537.6)	217.7 (153.7 to 308.3)	228.1 (161.9 to 321.5)	331.4 (238.4 to 460.5)

No statistical analyses for this end point

Secondary: Diphtheria (Anti-D) GMC at Screening by each Boostrix formulation [Primary Study]

Top of page

End point title

Diphtheria (Anti-D) GMC at Screening by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum). The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	51	49	49	52	50
Units: (IU/mL)
geometric mean (confidence interval 95%)	0.26 (0.18 to 0.39)	0.27 (0.17 to 0.42)	0.23 (0.16 to 0.32)	0.46 (0.33 to 0.64)	0.55 (0.42 to 0.73)	0.58 (0.43 to 0.78)

No statistical analyses for this end point

Secondary: Diphtheria (Anti-D) GMCs at Day 31 by each Boostrix formulation [Primary Study]

Top of page

End point title

Diphtheria (Anti-D) GMCs at Day 31 by each Boostrix formulation [Primary Study]

End point description

End point type

Secondary

End point timeframe

At Day 31

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	51	48	47	48	49
Units: (IU/mL)
geometric mean (confidence interval 95%)	1.3 (0.97 to 1.73)	1.18 (0.85 to 1.63)	1.76 (1.25 to 2.48)	2.11 (1.61 to 2.76)	2.2 (1.72 to 2.81)	3.29 (2.62 to 4.14)

No statistical analyses for this end point

Secondary: Tetanus (Anti-T) GMCs at Screening by each Boostrix formulation [Primary Study]

Top of page

End point title

Tetanus (Anti-T) GMCs at Screening by each Boostrix formulation [Primary Study]

End point description

Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. The analysis of this outcome measure was reported for each formulation of the dTpa (Boostrix) vaccine (300 μg or 500 μg of aluminum). The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	51	51	51	52	51
Units: (IU/mL)
geometric mean (confidence interval 95%)	1.14 (0.87 to 1.5)	1.1 (0.78 to 1.54)	0.88 (0.64 to 1.22)	1.35 (1.01 to 1.81)	1.56 (1.27 to 1.92)	1.68 (1.29 to 2.19)

No statistical analyses for this end point

Secondary: Tetanus (Anti-T) GMCs at Day 31 by each Boostrix formulation [Primary Study]

Top of page

End point title

Tetanus (Anti-T) GMCs at Day 31 by each Boostrix formulation [Primary Study]

End point description

End point type

Secondary

End point timeframe

At Day 31

End point values	RSV120_dTpa_RSV120(EX-US) - PPS-Primary Study	RSV60_dTpa_RSV120(EX-US) - PPS-Primary Study	dTpa_Placebo_RSV120(EX-US) - PPS-Primary Study	RSV120_dTpa_RSV120(US) - PPS-Primary Study	RSV60_dTpa_RSV120(US) - PPS-Primary Study	dTpa_Placebo_RSV120(US) - PPS-Primary Study
Number of subjects analysed	49	51	48	49	51	49
Units: (IU/mL)
geometric mean (confidence interval 95%)	5.57 (4.64 to 6.7)	5.3 (4.52 to 6.21)	6.74 (5.79 to 7.84)	6.09 (4.98 to 7.45)	6.27 (5.29 to 7.44)	8.32 (6.88 to 10.05)

No statistical analyses for this end point

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Screening [Primary Study]

Top of page

End point title

Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Screening [Primary Study] ^[15]

End point description

Serological assays for the determination of IgG antibodies against Bordetella pertussis: anti-PT, anti-FHA and anti-PRN were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups [RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

Notes
[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The analysis was only performed on the groups that received the dTpa vaccine.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	100	103	102
Units: IU/mL
geometric mean (confidence interval 95%)
Anti-PT	7.47 (5.83 to 9.57)	6.56 (5.20 to 8.28)	6.90 (5.36 to 8.89)
Anti-FHA	31.9 (25.3 to 40.2)	31.9 (25.6 to 39.8)	28.6 (23.5 to 34.9)
Anti-PRN	42.6 (31.6 to 57.4)	39.6 (29.6 to 52.9)	28.4 (20.7 to 38.9)

No statistical analyses for this end point

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Day 31 [Primary Study]

Top of page

End point title

Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Day 31 [Primary Study] ^[16]

End point description

End point type

Secondary

End point timeframe

At Day 31

Notes
[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The analysis was only performed on the groups that received the dTpa vaccine.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	98	102	97
Units: IU/mL
geometric mean (confidence interval 95%)
Anti-PT	50.10 (41.04 to 61.17)	45.08 (38.00 to 53.48)	59.51 (49.71 to 71.23)
Anti-FHA	210.3 (181.4 to 243.8)	192.9 (164.2 to 226.6)	265.6 (224.7 to 313.8)
Anti-PRN	259.6 (205.8 to 327.4)	221.3 (179.5 to 272.9)	361.1 (289.1 to 451.1)

No statistical analyses for this end point

Secondary: Diphtheria (Anti-D) GMC at Day 31 [Primary Study]

Top of page

End point title

Diphtheria (Anti-D) GMC at Day 31 [Primary Study] ^[17]

End point description

Serological assays for the determination of IgG antibodies against anti-D were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups [RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Day 31

Notes
[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The analysis was only performed on the groups that received the dTpa vaccine.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	96	99	97
Units: IU/mL
geometric mean (confidence interval 95%)	1.65 (1.35 to 2.01)	1.59 (1.29 to 1.97)	2.42 (1.96 to 2.99)

No statistical analyses for this end point

Secondary: Diphtheria (Anti-D) GMCs at Screening [Primary Study]

Top of page

End point title

Diphtheria (Anti-D) GMCs at Screening [Primary Study] ^[18]

End point description

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

Notes
[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The analysis was only performed on the groups that received the dTpa vaccine.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	98	103	99
Units: IU/mL
geometric mean (confidence interval 95%)	0.35 (0.27 to 0.45)	0.39 (0.30 to 0.51)	0.36 (0.28 to 0.47)

No statistical analyses for this end point

Secondary: Tetanus (Anti-T) GMCs at Screening [Primary Study]

Top of page

End point title

Tetanus (Anti-T) GMCs at Screening [Primary Study] ^[19]

End point description

Serological assays for the determination of IgG antibodies against anti-T were performed by ELISA. Analysis of this outcome measure was reported for the Pooled groups [RSV120_dTpa_RSV120(Pooled), RSV60_dTpa_RSV120(Pooled) and dTpa_Placebo_RSV120(Pooled)] as the two formulations of the dTpa vaccine (containing 300 μg or 500 μg of aluminum) showed similar immunogenicity and safety profiles in previous studies. The analysis was performed on the PPS - Primary Study which consisted of all subjects from the ES - Primary Study, who complied with protocol defined procedures and for whom immunogenicity results were available for the specified assay and time point.

End point type

Secondary

End point timeframe

At Screening (Day -7 to Day 1)

Notes
[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The analysis was only performed on the groups that received the dTpa vaccine.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	100	103	102
Units: IU/mL
geometric mean (confidence interval 95%)	1.24 (1.02 to 1.51)	1.31 (1.08 to 1.60)	1.22 (0.98 to 1.51)

No statistical analyses for this end point

Secondary: Tetanus (Anti-T) GMCs at Day 31 [Primary Study]

Top of page

End point title

Tetanus (Anti-T) GMCs at Day 31 [Primary Study] ^[20]

End point description

End point type

Secondary

End point timeframe

At Day 31

Notes
[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The analysis was only performed on the groups that received the dTpa vaccine.

End point values	RSV120_dTpa_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)
Number of subjects analysed	98	102	97
Units: IU/mL
geometric mean (confidence interval 95%)	5.83 (5.10 to 6.66)	5.76 (5.13 to 6.47)	7.49 (6.64 to 8.46)

No statistical analyses for this end point

Adverse events

Top of page

Timeframe for reporting adverse events

Solicited adverse events(AEs) were collected during the 7-day follow-up period and unsolicited AEs during the 30-day follow-up period after any vaccination. Serious AEs were collected from Day 1 (Primary Study) to the Study End (Day 181, Extension Study).

Adverse event reporting additional description

As per the analysis plan, AEs were reported for the pooled groups, as the 2 formulations of dTpa vaccine showed similar safety profiles in previous studies. Total number of subjects affected by Other AEs were obtained from the rows with the maximum number of events.Results of Other AEs were summarized by two periods (Primary & Extension Study).

Assessment type

Systematic

Dictionary name

MedDRA

Dictionary version

24.1

Reporting group title

RSV120_dTpa_RSV120(Pooled)

Reporting group description

Reporting group title

dTpa_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

RSV120_Placebo_RSV120(Pooled)

Reporting group description

Reporting group title

RSV60_dTpa_RSV120(Pooled)

Reporting group description

Serious adverse events	RSV120_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)
Total subjects affected by serious adverse events
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
number of deaths (all causes)	0	0	0	0	0
number of deaths resulting from adverse events	0	0	0	0	0
Injury, poisoning and procedural complications
Radius fracture
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Ulna fracture
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Wrist fracture
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Infections and infestations
Pyelonephritis
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0%

Non-serious adverse events	RSV120_dTpa_RSV120(Pooled)	dTpa_Placebo_RSV120(Pooled)	RSV60_Placebo_RSV120(Pooled)	RSV120_Placebo_RSV120(Pooled)	RSV60_dTpa_RSV120(Pooled)
Total subjects affected by non serious adverse events
subjects affected / exposed	92 / 101 (91.09%)	89 / 102 (87.25%)	82 / 102 (80.39%)	90 / 101 (89.11%)	91 / 103 (88.35%)
Vascular disorders
Hypertension - Extension Study
subjects affected / exposed ^[1]	0 / 39 (0.00%)	1 / 46 (2.17%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	2	0	0	0
General disorders and administration site conditions
Injection site pain - Primary Study
subjects affected / exposed	86 / 101 (85.15%)	81 / 102 (79.41%)	60 / 102 (58.82%)	62 / 101 (61.39%)	84 / 103 (81.55%)
occurrences all number	204	170	128	136	200
Fatigue - Primary Study
subjects affected / exposed	42 / 101 (41.58%)	38 / 102 (37.25%)	34 / 102 (33.33%)	40 / 101 (39.60%)	39 / 103 (37.86%)
occurrences all number	86	77	69	83	79
Injection site erythema - Primary Study
subjects affected / exposed	7 / 101 (6.93%)	6 / 102 (5.88%)	7 / 102 (6.86%)	6 / 101 (5.94%)	8 / 103 (7.77%)
occurrences all number	18	12	14	12	18
Injection site swelling - Primary Study
subjects affected / exposed	5 / 101 (4.95%)	4 / 102 (3.92%)	6 / 102 (5.88%)	8 / 101 (7.92%)	3 / 103 (2.91%)
occurrences all number	12	8	12	16	6
Pyrexia - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	7 / 102 (6.86%)	4 / 102 (3.92%)	4 / 101 (3.96%)	3 / 103 (2.91%)
occurrences all number	4	14	8	8	6
Injection site bruising - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	2 / 102 (1.96%)	1 / 102 (0.98%)	2 / 101 (1.98%)	4 / 103 (3.88%)
occurrences all number	4	4	2	6	8
Administration site erythema - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	3 / 101 (2.97%)	4 / 103 (3.88%)
occurrences all number	0	0	1	3	4
Administration site pain - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	1 / 102 (0.98%)	1 / 102 (0.98%)	1 / 101 (0.99%)	3 / 103 (2.91%)
occurrences all number	2	1	1	1	3
Injection site pruritus - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	3 / 102 (2.94%)	1 / 102 (0.98%)	2 / 101 (1.98%)	0 / 103 (0.00%)
occurrences all number	2	6	2	4	0
Injection site haemorrhage - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	2 / 101 (1.98%)	1 / 103 (0.97%)
occurrences all number	0	0	2	4	2
Administration site swelling - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	4 / 103 (3.88%)
occurrences all number	1	0	0	0	4
Vaccination site nodule - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	2 / 103 (1.94%)
occurrences all number	2	2	0	0	4
Malaise - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	2 / 101 (1.98%)	0 / 103 (0.00%)
occurrences all number	2	0	0	4	0
Pain - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	1 / 102 (0.98%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	2	2	0	0
Injection site warmth - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	2 / 102 (1.96%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	4	0	2	0
Axillary pain - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	2	0	2	0	2
Chills - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	2	2	0
Injection site induration - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	2	0	0	0
Influenza like illness - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	2	0	2
Feeling cold - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Hangover - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Injection site discomfort - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Injection site haematoma - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Injection site discolouration - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	2	0	0	0
Injection site rash - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	2	0	0	0
Injection site pain - Extension Study
subjects affected / exposed ^[2]	34 / 39 (87.18%)	18 / 46 (39.13%)	35 / 41 (85.37%)	36 / 41 (87.80%)	37 / 46 (80.43%)
occurrences all number	68	38	70	74	74
Fatigue - Extension Study
subjects affected / exposed ^[3]	10 / 39 (25.64%)	16 / 46 (34.78%)	19 / 41 (46.34%)	15 / 41 (36.59%)	17 / 46 (36.96%)
occurrences all number	23	32	39	31	35
Injection site erythema - Extension Study
subjects affected / exposed ^[4]	7 / 39 (17.95%)	1 / 46 (2.17%)	6 / 41 (14.63%)	4 / 41 (9.76%)	4 / 46 (8.70%)
occurrences all number	14	2	12	8	8
Pyrexia - Extension Study
subjects affected / exposed ^[5]	0 / 39 (0.00%)	1 / 46 (2.17%)	5 / 41 (12.20%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	2	10	0	2
Injection site swelling - Extension Study
subjects affected / exposed ^[6]	5 / 39 (12.82%)	1 / 46 (2.17%)	2 / 41 (4.88%)	3 / 41 (7.32%)	4 / 46 (8.70%)
occurrences all number	10	2	4	6	8
Injection site pruritus - Extension Study
subjects affected / exposed ^[7]	0 / 39 (0.00%)	0 / 46 (0.00%)	2 / 41 (4.88%)	1 / 41 (2.44%)	0 / 46 (0.00%)
occurrences all number	0	0	4	2	0
Malaise - Extension Study
subjects affected / exposed ^[8]	1 / 39 (2.56%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	2	0	0	0	2
Administration site pain - Extension Study
subjects affected / exposed ^[9]	1 / 39 (2.56%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	1	0	0	0	0
Injection site induration - Extension Study
subjects affected / exposed ^[10]	1 / 39 (2.56%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	2	0	0	0	0
Inflammation - Extension Study
subjects affected / exposed ^[11]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 46 (0.00%)
occurrences all number	0	0	0	2	0
Influenza like illness - Extension Study
subjects affected / exposed ^[12]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Injection site haemorrhage - Extension Study
subjects affected / exposed ^[13]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Pain - Extension Study
subjects affected / exposed ^[14]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Administration site swelling - Extension Study
subjects affected / exposed ^[15]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	1
Injection site lymphadenopathy - Extension Study
subjects affected / exposed ^[16]	0 / 39 (0.00%)	1 / 46 (2.17%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	2	0	0	0
Immune system disorders
Drug hypersensitivity - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	0	0	0
Seasonal allergy - Extension Study
subjects affected / exposed ^[17]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	2
Reproductive system and breast disorders
Dysmenorrhoea - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	2	0	0
Vaginal discharge - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Intermenstrual bleeding - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Dysmenorrhoea - Extension Study
subjects affected / exposed ^[18]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain - Primary Study
subjects affected / exposed	3 / 101 (2.97%)	0 / 102 (0.00%)	1 / 102 (0.98%)	2 / 101 (1.98%)	1 / 103 (0.97%)
occurrences all number	8	0	2	4	2
Cough - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	2 / 102 (1.96%)	1 / 101 (0.99%)	1 / 103 (0.97%)
occurrences all number	0	0	4	2	2
Rhinorrhoea - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	2	2	0
Nasal congestion - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	2 / 103 (1.94%)
occurrences all number	0	0	0	0	4
Oropharyngeal pain - Extension Study
subjects affected / exposed ^[19]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	3 / 41 (7.32%)	1 / 46 (2.17%)
occurrences all number	0	0	0	6	2
Nasal congestion - Extension Study
subjects affected / exposed ^[20]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Rhinorrhoea - Extension Study
subjects affected / exposed ^[21]	0 / 39 (0.00%)	1 / 46 (2.17%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	2	0	0	0
Psychiatric disorders
Insomnia - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	1 / 101 (0.99%)	1 / 103 (0.97%)
occurrences all number	0	0	2	2	2
Affect lability - Extension Study
subjects affected / exposed ^[22]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Poor quality sleep - Extension Study
subjects affected / exposed ^[23]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	2
Injury, poisoning and procedural complications
Procedural pain - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	2	0	0	2	0
Thermal burn - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	2	0	0	0
Muscle strain - Extension Study
subjects affected / exposed ^[24]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Contusion - Extension Study
subjects affected / exposed ^[25]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	2
Cardiac disorders
Palpitations - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Nervous system disorders
Headache - Primary Study
subjects affected / exposed	47 / 101 (46.53%)	37 / 102 (36.27%)	42 / 102 (41.18%)	47 / 101 (46.53%)	38 / 103 (36.89%)
occurrences all number	105	76	92	101	81
Dizziness - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	1 / 102 (0.98%)	1 / 102 (0.98%)	2 / 101 (1.98%)	0 / 103 (0.00%)
occurrences all number	4	2	2	4	0
Disturbance in attention - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	0	0	0
Migraine - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Sciatica - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	0	0	0
Head discomfort - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	2	0	0	0
Neuralgia - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	2	0	0	0
Sleep deficit - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Post-traumatic headache - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Headache - Extension Study
subjects affected / exposed ^[26]	11 / 39 (28.21%)	16 / 46 (34.78%)	23 / 41 (56.10%)	15 / 41 (36.59%)	15 / 46 (32.61%)
occurrences all number	24	34	50	31	32
Migraine with aura - Extension Study
subjects affected / exposed ^[27]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	2
Blood and lymphatic system disorders
Lymphadenopathy - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	2 / 102 (1.96%)	0 / 101 (0.00%)	2 / 103 (1.94%)
occurrences all number	2	0	4	0	4
Lymphadenitis - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	0	0	0
Ear and labyrinth disorders
Ear pain - Extension Study
subjects affected / exposed ^[28]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Eye disorders
Vision blurred - Extension Study
subjects affected / exposed ^[29]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	2
Gastrointestinal disorders
Gastrointestinal disorder - Primary Study
subjects affected / exposed	24 / 101 (23.76%)	28 / 102 (27.45%)	29 / 102 (28.43%)	29 / 101 (28.71%)	28 / 103 (27.18%)
occurrences all number	50	56	58	60	57
Nausea - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	2	0	2	0	2
Dyspepsia - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	2	0	0	0
Toothache - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	1 / 103 (0.97%)
occurrences all number	0	0	0	2	2
Abdominal distension - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Diarrhoea - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Hyperchlorhydria - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Abdominal pain - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Gastrointestinal disorder - Extension Study
subjects affected / exposed ^[30]	4 / 39 (10.26%)	7 / 46 (15.22%)	10 / 41 (24.39%)	10 / 41 (24.39%)	7 / 46 (15.22%)
occurrences all number	9	14	20	20	14
Oesophageal spasm - Extension Study
subjects affected / exposed ^[31]	0 / 39 (0.00%)	1 / 46 (2.17%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	2	0	0	2
Abdominal pain - Extension Study
subjects affected / exposed ^[32]	1 / 39 (2.56%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	2	0	0	0	0
Diarrhoea - Extension Study
subjects affected / exposed ^[33]	1 / 39 (2.56%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	2	0	0	0	0
Vomiting - Extension Study
subjects affected / exposed ^[34]	1 / 39 (2.56%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	2	0	0	0	0
Skin and subcutaneous tissue disorders
Rash - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	1 / 101 (0.99%)	1 / 103 (0.97%)
occurrences all number	0	2	0	2	2
Dermatitis - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	0	0	0
Dermatitis allergic - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	0	0	0
Night sweats - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Night sweats - Extension Study
subjects affected / exposed ^[35]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 46 (0.00%)
occurrences all number	0	0	0	2	0
Rash - Extension Study
subjects affected / exposed ^[36]	0 / 39 (0.00%)	1 / 46 (2.17%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	2	0	0	0
Musculoskeletal and connective tissue disorders
Myalgia - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	0 / 102 (0.00%)	4 / 102 (3.92%)	4 / 101 (3.96%)	1 / 103 (0.97%)
occurrences all number	4	0	8	8	2
Back pain - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	2 / 102 (1.96%)	2 / 102 (1.96%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	4	4	4	0	2
Neck pain - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	4	2	0	0	2
Arthralgia - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	2 / 102 (1.96%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	4	2	0
Muscle tightness - Primary Study
subjects affected / exposed	2 / 101 (1.98%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	4	0	0	0	0
Pain in extremity - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	2	0	0	0	2
Musculoskeletal pain - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	0	0	0	0
Musculoskeletal stiffness - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Pain in jaw - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	2	0	0	0
Limb discomfort - Extension Study
subjects affected / exposed ^[37]	1 / 39 (2.56%)	1 / 46 (2.17%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	2	2	0	0	0
Arthralgia - Extension Study
subjects affected / exposed ^[38]	1 / 39 (2.56%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	2	0	0	0	0
Myalgia - Extension Study
subjects affected / exposed ^[39]	0 / 39 (0.00%)	1 / 46 (2.17%)	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 46 (0.00%)
occurrences all number	0	2	0	2	0
Infections and infestations
Upper respiratory tract infection - Primary Study
subjects affected / exposed	8 / 101 (7.92%)	5 / 102 (4.90%)	2 / 102 (1.96%)	9 / 101 (8.91%)	4 / 103 (3.88%)
occurrences all number	16	10	4	18	8
Nasopharyngitis - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	3 / 102 (2.94%)	7 / 102 (6.86%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	2	6	14	2	0
Urinary tract infection - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	2 / 102 (1.96%)	1 / 102 (0.98%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	2	4	2	0	2
Sinusitis - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	2 / 102 (1.96%)	3 / 102 (2.94%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	4	6	0	0
Rhinitis - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	1 / 102 (0.98%)	1 / 102 (0.98%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	2	2	2	2	0
Gastroenteritis - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	2 / 102 (1.96%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	2	4	2	0
Pharyngitis - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	2	0	2	0	2
Tooth infection - Primary Study
subjects affected / exposed	1 / 101 (0.99%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	2	2	0	0	0
Conjunctivitis - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Pharyngitis bacterial - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Pharyngitis streptococcal - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Viral infection - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	1 / 101 (0.99%)	0 / 103 (0.00%)
occurrences all number	0	0	0	2	0
Chlamydial infection - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	2	0	0	0
Bacterial vaginosis - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	1 / 102 (0.98%)	0 / 102 (0.00%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	2	0	0	0
Ear infection - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Cystitis - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Gingivitis - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	1 / 102 (0.98%)	0 / 101 (0.00%)	0 / 103 (0.00%)
occurrences all number	0	0	2	0	0
Oral herpes - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Otitis media - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Otitis media acute - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Vaginitis chlamydial - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Vulvovaginal mycotic infection - Primary Study
subjects affected / exposed	0 / 101 (0.00%)	0 / 102 (0.00%)	0 / 102 (0.00%)	0 / 101 (0.00%)	1 / 103 (0.97%)
occurrences all number	0	0	0	0	2
Pharyngitis - Extension Study
subjects affected / exposed ^[40]	0 / 39 (0.00%)	0 / 46 (0.00%)	2 / 41 (4.88%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	4	0	0
Nasopharyngitis - Extension Study
subjects affected / exposed ^[41]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	2	0	2
Bronchitis - Extension Study
subjects affected / exposed ^[42]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Ear infection - Extension Study
subjects affected / exposed ^[43]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Gastroenteritis - Extension Study
subjects affected / exposed ^[44]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	2	0	0
Pyelonephritis - Extension Study
subjects affected / exposed ^[45]	0 / 39 (0.00%)	0 / 46 (0.00%)	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	0	1	0	0
Respiratory tract infection - Extension Study
subjects affected / exposed ^[46]	0 / 39 (0.00%)	1 / 46 (2.17%)	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 46 (0.00%)
occurrences all number	0	2	0	0	0
Tonsillitis - Extension Study
subjects affected / exposed ^[47]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 46 (0.00%)
occurrences all number	0	0	0	2	0
Sinusitis - Extension Study
subjects affected / exposed ^[48]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	2
Upper respiratory tract infection - Extension Study
subjects affected / exposed ^[49]	0 / 39 (0.00%)	0 / 46 (0.00%)	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 46 (2.17%)
occurrences all number	0	0	0	0	2

Notes
[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[15] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[16] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[17] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[18] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[19] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[20] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[21] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[22] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[23] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[24] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[25] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[26] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[27] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[28] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[29] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[30] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[31] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[32] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[33] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[34] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[35] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[36] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[37] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[38] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[39] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[40] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[41] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[42] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[43] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[44] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[45] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[46] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[47] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[48] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).
[49] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Out of 509 subjects who completed the Primary Study, 296 subjects did not participate in the Extension Study due to non-compliance of protocol requirements (e.g. completion of the diary card, return for follow-up visits, no willingness/no informed consent obtained).

More information

Top of page

Were there any global substantial amendments to the protocol? Yes

23 Jan 2020

The amendment has following changes: To collect immunogenicity data to 12 months post dosing. Long term persistence data will be useful to inform the boosting schedule for women entering successive pregnancies. Unblinding after Day 181 will still occur and the extended study (epoch 4) will be open label. In addition, several discrepancies with the protocol with the study procedures manual were aligned.

03 Apr 2020

The sponsor has decided not to implement the 6-month extension for prolonged immunogenicity described under Amendment 2. The rationale for taking this decision is that the sponsor intends to submit an amendment that will enrol new participants (Cohort 2) to allow a more robust assessment of non-inferiority of Boostrix response in co-administration with RSVPreF3. An assessment of antibody persistence will be included in these newly enrolled subjects. Hence the evaluation of prolonged immunogenicity in Cohort 1 has become redundant. Changes not related to the study design of the extension phase in Amendment 2 were not removed for this amendment.

28 Aug 2020

This study has been amended to administer a 2nd dose of the 120 μg RSVPreF3 Maternal investigational vaccine to all consenting subjects within a 6-month period from the beginning of 12 months to the beginning of 18 months following initial immunization (≥12 to <18 months).This extension part of the study will use non-pregnant women as a proxy for women who may require additional dosing in successive pregnancies. Specifically, this extension will provide information on: long term immunogenicity of a 1st dose of 60 μg or 120 μg RSVPreF3 vaccine and safety and immunogenicity of 2nd dose of 120 μg RSVPreF3 vaccine. In addition, this protocol amendment outlines measures that may be applicable during special circumstances (e.g., COVID-19 pandemic). The purpose of the amendment is to protect the subject’s welfare, and as far as possible ensure the potential benefit to the subject and promote data integrity.

Were there any global interruptions to the trial? No

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: Percentage of subjects with any solicited local adverse event (AEs) [Primary Study]

Primary: Percentage of subjects with any solicited local adverse event (AEs) [Primary Study]

Primary: Percentage of subjects with any solicited general AEs [Primary Study]

Primary: Percentage of subjects with any solicited general AEs [Primary Study]

Primary: Percentage of subjects with any unsolicited AEs [Primary Study]

Primary: Percentage of subjects with any unsolicited AEs [Primary Study]

Primary: Number of subjects with any SAEs [Primary Study]

Primary: Number of subjects with any SAEs [Primary Study]

Primary: Percentage of subjects with any solicited local AEs [Extension Study]

Primary: Percentage of subjects with any solicited local AEs [Extension Study]

Primary: Percentage of subjects any solicited general AEs [Extension Period]

Primary: Percentage of subjects any solicited general AEs [Extension Period]

Primary: Percentage of subjects with any unsolicited AEs [Extension Period]

Primary: Percentage of subjects with any unsolicited AEs [Extension Period]

Primary: Number of subjects with any SAEs [Extension Period]

Primary: Number of subjects with any SAEs [Extension Period]

Primary: RSV A neutralizing antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]

Primary: RSV A neutralizing antibody Geometric Mean Titers (GMTs) at Screening [Primary Study]

Primary: RSV A neutralizing antibody GMTs at Day 8 [Primary Study]

Primary: RSV A neutralizing antibody GMTs at Day 8 [Primary Study]

Primary: RSV A neutralizing antibody GMTs at Day 31 [Primary Study]

Primary: RSV A neutralizing antibody GMTs at Day 31 [Primary Study]

Primary: RSV PreF3 IgG antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]

Primary: RSV PreF3 IgG antibody Geometric Mean Concentration (GMCs) at Screening [Primary Study]

Primary: RSV PreF3 IgG GMCs at Day 8 [Primary Study]

Primary: RSV PreF3 IgG GMCs at Day 8 [Primary Study]

Primary: RSV PreF3 IgG GMCs at Day 31 [Primary Study]

Primary: RSV PreF3 IgG GMCs at Day 31 [Primary Study]

Secondary: Percentage of subjects with any solicited local adverse event (AEs) by each Boostrix formulation [Primary Study]

Secondary: Percentage of subjects with any solicited local adverse event (AEs) by each Boostrix formulation [Primary Study]

Secondary: Percentage of subjects with any solicited general AEs by each Boostrix formulation [Primary Study]

Secondary: Percentage of subjects with any solicited general AEs by each Boostrix formulation [Primary Study]

Secondary: Percentage of subjects with any unsolicited AEs by each Boostrix formulation [Primary Study]

Secondary: Percentage of subjects with any unsolicited AEs by each Boostrix formulation [Primary Study]

Secondary: Number of subjects with any SAEs by each Boostrix formulation [Primary Study]

Secondary: Number of subjects with any SAEs by each Boostrix formulation [Primary Study]

Secondary: Number of subjects with any SAEs from 1st vaccination to Day 181 [Primary Study]

Secondary: Number of subjects with any SAEs from 1st vaccination to Day 181 [Primary Study]

Secondary: Number of subjects with any SAEs from 1st vaccination to Day 181 by each Boostrix formulation [Primary Study]

Secondary: Number of subjects with any SAEs from 1st vaccination to Day 181 by each Boostrix formulation [Primary Study]

Secondary: Number of subjects with any SAEs from 2nd vaccination to Day 181 post 2nd vaccination [Extension Period]

Secondary: Number of subjects with any SAEs from 2nd vaccination to Day 181 post 2nd vaccination [Extension Period]

Secondary: RSV A neutralizing GMTs at Screening by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at Screening by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at Day 8 by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at Day 8 by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at Day 31 by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at Day 31 by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

Secondary: RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

Secondary: RSV A neutralizing GMTs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

Secondary: RSV A neutralizing GMTs at Day 31 post 2nd vaccination [Extension Study]

Secondary: RSV A neutralizing GMTs at Day 31 post 2nd vaccination [Extension Study]

Secondary: RSV PreF3 IgG GMCs at Screening by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at Screening by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at Day 8 by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at Day 8 by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at Day 31 by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at Day 31 by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination by each Boostrix formulation [Primary Study]

Secondary: RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

Secondary: RSV PreF3 IgG GMCs at single time point between 12 to 18 months post 1st vaccination [Primary Study]

Secondary: RSV PreF3 IgG GMCs at Day 31 post 2nd vaccination [Extension Study]

Secondary: RSV PreF3 IgG GMCs at Day 31 post 2nd vaccination [Extension Study]

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Screening by each Boostrix formulation [Primary Study]

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Screening by each Boostrix formulation [Primary Study]

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Day 31 by each Boostrix formulation [Primary Study]

Secondary: Pertussis toxoid (anti-PT), Filamentous hemagglutinin (anti-FHA) and Pertactin (anti-PRN) GMCs at Day 31 by each Boostrix formulation [Primary Study]

Secondary: Diphtheria (Anti-D) GMC at Screening by each Boostrix formulation [Primary Study]